Effects of lanreotide autogel on growth hormone, insulinlike growth factor 1, and tumor size in acromegaly: A 1-year prospective multicenter study

Endocrine Practice

Volumn 14, Issue 7, 2008, Pages 846-855

  Attanasio, Roberto ^a,b   Lanzi, Roberto ^c   Losa, Marco ^c   Valentini, Ferdinando ^d   Grimaldi, Franco ^e   De Menis, Ernesto ^f   Davì, Maria Vittoria ^g   Battista, Claudia ^h   Castello, Roberto ⁱ   Cremonini, Nadia ^j   Razzore, Paola ^k   Rosato, Francesca ^l   Montini, Marcella ^a   Cozzi, Renato ^m  

^a Joined Hospitals of Bergamo   (Italy)

^b IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^e SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^f Treviso Hospital   (Italy)

^g Verona Hospital   (Italy)

^h The House for Relief of Suffering   (Italy)

ⁱ UNIVERSITY OF VERONA   (Italy)

^j Major Hospital   (Italy)

^k S CROCE E CARLE HOSPITAL   (Italy)

^l VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^m OSPEDALE NIGUARDA CA GRANDA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GLUCOSE; GROWTH HORMONE; LIPID; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; CYCLOPEPTIDE; DRUG DERIVATIVE; HUMAN GROWTH HORMONE; SOMATOSTATIN;

ACROMEGALY; ADENOMA; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SIZE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLUCOSE METABOLISM; GROWTH HORMONE BLOOD LEVEL; HORMONAL REGULATION; HORMONE DETERMINATION; HUMAN; HUMAN TISSUE; HYPOPHYSIS FUNCTION; IRRADIATION; MACROADENOMA; MALE; MICROADENOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROSURGERY; PROSPECTIVE STUDY; TUMOR VOLUME; DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION;

ACROMEGALY; ADULT; AGED; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INJECTIONS, SUBCUTANEOUS; INSULIN-LIKE GROWTH FACTOR I; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; SOMATOSTATIN;

EID: 64749112299     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.14.7.846     Document Type: Article

References (41)

1. Melmed S. Medical progress: Acromegaly [erratum in N Engl J Med. 2007;356:879]. N Engl J Med. 2006;355: 2558-2573.
2. Holdaway IM, Rajasoorya CR, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab. 2004;89:667-674.
3. Melmed S, Casanueva FF, Cavagnini F, et al. Guidelines for acromegaly management. J Clin Endocrinol Metab. 2002;87:4054-4058.
4. Heron I, Thomas F, Dero M, et al. Treatment of acromegaly with sustained-release lanreotide. A new somatostatin analog [article in French]. Presse Med. 1993;22:526-531.
5. Giusti M, Gussoni G, Cuttica CM, Giordano G. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. J Clin Endocrinol Metab. 1996;81:2089-2097.
6. Caron P, Morange-Ramos I, Cogne M, Jaquet P. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab. 1997;82:18-22.
7. Hradec J, Kral J, Janota T, et al. Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog). Am J Cardiol. 1999;83:1506-1509.
8. Colao A, Marzullo P, Vallone G, et al. Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months. Clin Endocrinol (Oxf). 1999;51:611-618.
9. Colao A, Marzullo P, Lombardi G. Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. Eur J Endocrinol. 2002;146:303-309.
10. Bronstein M, Musolino N, Jallad R, et al. Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days. Clin Endocrinol (Oxf). 2005;63:514-519.
11. Bevan JS, Newell-Price J, Wass JAH, et al. Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective. Clin Endocrinol (Oxf). 2008;63:343-349.
12. Di Chiro G, Nelson KB. The volume of the sella turcica. Am J Roentgenol Radium Ther Nucl Med. 1962;87:989-1008.
13. Colao A, Pivonello R, Auriemma RS, et al. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab. 2006;91:2112-2118.
14. Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol. 2005;152:379-387.
15. Biermasz NR, Pereira AM, Neelis KJ, Roelfsema F, Romijn JA. Role of radiotherapy in the management of acromegaly. Exp Rev Endocrinol Metab. 2006;1:449-460.
16. Attanasio R, Epaminonda P, Motti E, et al. Gamma-knife radiosurgery in acromegaly: a 4-year-follow-up study. J Clin Endocrinol Metab. 2003;88:3105-3112.
17. Castinetti F, Taieb D, Kuhn JM, et al. Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. J Clin Endocrinol Metab. 2005;90:4483-4488.
18. Jezková J, Marek J, Hána V, et al. Gamma knife radiosurgery for acromegaly-long-term experience. Clin Endocrinol (Oxf). 2006;64:588-595.
19. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2005;90:4465-4473.
20. Cozzi R, Attanasio R, Montini M, et al. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab. 2003;88:3090-3098.
21. Cozzi R, Montini M, Attanasio R, et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study on its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab. 2006;91:1397-1403.
22. Attanasio R, Baldelli R, Pivonello R, et al. Lanreotide 60 mg, a new long-acting formulation: effectiveness chronic treatment of acromegaly. J Clin Endocrinol Metab. 2003;88:5258-5265.
23. Caron P, Beckers A, Cullen DR, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab. 2002;87:99-104.
24. Lucas T, Astorga R; Spanish-Portuguese Multicentre Autogel Study Group on Acromegaly. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial. Clin Endocrinol (Oxf). 2006;65:320-326.
25. Caron P, Cogne M, Raingeard I, Bex-Bachellerie V, Kuhn JM. Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clin Endocrinol (Oxf). 2006;64:209-214.
26. Ronchi CL, Boschetti M, Degli Uberti EC, et al; Italian Multicenter Autogel Study Group in Acromegaly. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin Endocrinol (Oxf). 2007; 67:512-519.
27. Caron P, Bex M, Cullen DR, et al; Group for Lanreotide Autogel Long-Term Study on Acromegaly. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clin Endocrinol (Oxf). 2004;60:734-740.
28. Abrams P, Alexopoulou O, Abs R, Maiter D, Verhelst J. Optimalization and cost management of lanreotide-Autogel therapy in acromegaly. Eur J Endocrinol. 2007; 157:571-577.
29. Newman CB, Melmed S, George A, et al. Octreotide as primary treatment for acromegaly. J Clin Endocrinol Metab. 1998;83:3034-3040.
30. Murray RD, Kim K, Ren SG, Chelly M, Umehara Y, Melmed S. Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. J Clin Invest. 2004;114:349-356.
31. Bevan JS. Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab. 2005;90:1856-1863.
32. Attanasio R, Barausse M, Cozzi R. GH/IGF-I normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotide. J Endocrinol Invest. 2001;24:209-216.
33. Alexopoulou O, Abrams P, Verhelst J, et al. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol. 2004;151:317-324.
34. Baldelli R, Colao A, Razzore P, et al. Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). J Clin Endocrinol Metab. 2000;85:4099-4103.
35. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis. and management. Endocr Rev. 2004;25:102-152.
36. Steffin B, Gutt B, Bidlingmaier M, Dieterle C, Oltmann F, Schopohl J. Effects of the long-acting somatostatin analogue lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly. Eur J Endocrinol. 2006;155: 73-78.
37. Arosio M, Sartore G, Rossi CM, Casati G, Faglia G, Manzato E. LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy. Italian Multicenter Octreotide Study Group. Atherosclerosis. 2000;151:551-557.
38. Attanasio R, Mainolfi A, Grimaldi F, et al. Somatostatin analogs and gallstones: a retrospective survey on a large series of acromegalic patients. J Endocrinol Invest. In press.
39. Cozzi R, Dallabonzana D, Attanasio R, Barausse M, Oppizzi G. A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly. Eur J Endocrinol. 1999;141:267-271.
40. Turner HE, Vadivale A, Keenan J, Wass JA. A comparison of lanreotide and octreotide LAR for treatment of acromegaly. Clin Endocrinol (Oxf). 1999;51:275-280.
41. Andries M, Glintborg D, Kvistborg A, Hagen C, Andersen M. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-I in patients with acromegaly. Clin Endocrinol (Oxf). 2008;68:473-480.